Theraclion Announces World’s Largest & First Asian Study Demonstrating Benign Thyroid Nodule Treatment Efficacy with Echotherapy

  • Median volume reduction of 68.3% at six months follow-up in 73-patient cohort
  • Single treatment session treatment sufficient for ablation
  • Minimal post-operative pain
  • Published in American Thyroid Association (ATA)’s official journal, Thyroid

MALAKOFF, France--()--Regulatory News:

THERACLION (Paris:ALTHE) (Alternext, FR0010120402 - ALTHE, PEA PME eligible), a company specialized in cutting-edge medical equipment for echotherapy, announced the publication of an asian study demonstrating that echotherapy using Echopulse® significantly reduces the size of large benign thyroid nodules. The study, entitled “Single-session high intensity focus ultrasound (HIFU) treatment in large-sized benign thyroid nodules” was published online on March 2, 2017 in the American Thyroid Association (ATA)’s official peer-reviewed journal, Thyroid.

The open-label, 73-patient study evaluated the efficacy of a single treatment of ultrasound-guided HIFU ablation employing the Echopulse® echotherapy system to treat small to large-sized benign thyroid nodules. Patients were divided into three groups depending on nodule size: small nodules <10 mL (Group 1), medium nodules between 10-30 mL (Group 2) and large nodules >30 mL (Group 3). The primary endpoint was nodule volume at six months with ablation success defined as more than a 50% reduction in nodule volume. Overall median volume reduction at six months was 68.3%. The treatment was well-tolerated with no reported serious side effects.

Professor Brian Lang, MD, The University of Hong Kong and principal investigator of this study, commented: “This study demonstrated that echotherapy is effective and safe on a wide range of predominantly-solid benign thyroid nodules with encouraging volume reductions at six months. These results demonstrated a very feasible alternative to conventional thyroid surgery, with significant reduction in nodule volume after just single-session treatment.”

David Caumartin, CEO of Theraclion added: “The size and density of the nodule has historically limited the effectiveness of echotherapy treatment. However, the BEAMOTION software introduced in early 2016 has enabled a much faster and focused treatment, making it possible to effectively treat large nodules. This is the first publication that provides the scientific evidence that echotherapy treats small-to-large thyroid nodules”.

“It is also the first publication on an Asian population, a geography, with China and Korea at the forefront, that we anticipate will be one of our biggest market in the near future,” concluded Sylvain Yon, Deputy CEO, Theraclion.

About Theraclion
Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound. Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 34 people, 50% of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website: www.theraclion.com

Theraclion is listed on Alternext Paris
PEA-PME eligible
Mnemonic: ALTHE - ISIN Code: FR0010120402

Contacts

Theraclion
David Caumartin
Chief Executive Officer
Tel.: +33 (0)1 55 48 90 70
david.caumartin@theraclion.com
or
NewCap
Financial Communication and Investor Relations
Emmanuel Huynh / Valentine Brouchot
Tel.: +33 (0)1 44 71 94 94
theraclion@newcap.eu
or
Kalima
Press Relations
Florence Calba, Tel.: + 33 (0)1 44 90 82 54
fcalba@kalima-rp.fr
or
The Ruth Group (U.S.)
Investor Relations / Public Relations
Robert Flamm / Kirsten Thomas
+1 646-536-7017 / +1 508-280-6592
rflamm@theruthgroup.com / thomas@theruthgroup.com

Contacts

Theraclion
David Caumartin
Chief Executive Officer
Tel.: +33 (0)1 55 48 90 70
david.caumartin@theraclion.com
or
NewCap
Financial Communication and Investor Relations
Emmanuel Huynh / Valentine Brouchot
Tel.: +33 (0)1 44 71 94 94
theraclion@newcap.eu
or
Kalima
Press Relations
Florence Calba, Tel.: + 33 (0)1 44 90 82 54
fcalba@kalima-rp.fr
or
The Ruth Group (U.S.)
Investor Relations / Public Relations
Robert Flamm / Kirsten Thomas
+1 646-536-7017 / +1 508-280-6592
rflamm@theruthgroup.com / thomas@theruthgroup.com